BioSpace News Archive

Noctrix Health, Inc. announced today that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation with strong support from insiders including OrbiMed and Treo Ventures.

Lexaria Bioscience Corp. announces a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies.

Plexium, Inc. announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase II AAVIATE® trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using suprachoroidal delivery. Wet AMD is a chronic, life-long disease with available anti-VEGF treatment options that may reduce the risk of blindness, but require frequent injections.

Inhibikase Therapeutics, Inc. today announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024.

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024.

Cellectis announced that it has drawn down the second tranche of €15 million under the credit facility agreement for up to €40 million entered into with the European Investment Bank on December 28, 2022.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Arvinas, Inc. announced that Jared Freedberg, J.D., has joined the company as General Counsel.

MEI Pharma, Inc. (Nasdaq: MEIP) today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gastrointestinal Cancers Symposium to be held January 18 – 20, 2024.